(4-chloro-6-phenyl-[1,3,5]triazin-2-yl)-methyl-amine | 1973-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: (4-chloro-6-phenyl-[1,3,5]triazin-2-yl)-methyl-amine
• 英文别名: 4-chloro-N-methyl-6-phenyl-1,3,5-triazin-2-amine；2-Chlor-4-methylamino-6-phenyl-s-triazin
• CAS: 1973-03-1
• 化学式: C₁₀H₉ClN₄
• 分子量: 220.661
• InChiKey: PIFHNYKEBUKOMB-UHFFFAOYSA-N

物化性质

• 沸点：
  420.9±28.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-哌啶甲酸 、 (4-chloro-6-phenyl-[1,3,5]triazin-2-yl)-methyl-amine 以 水 、 乙腈 为溶剂， 反应 24.0h， 生成 1-[4-(methylamino)-6-phenyl-1,3,5-triazin-2-yl]-4-piperidinecarboxylic acid
  参考文献：
  名称：

  [EN] NOVEL SEH INHIBITORS AND THEIR USE
  [FR] INHIBITEURS INÉDITS DE LA SEH ET LEUR UTILISATION

  摘要：

  该发明涉及新颖的sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体而言，该发明涉及符合以下式I的化合物：(I) 其中R1、R2、R3、R5a、R6a、A、B、Y、x和m的定义如下，并且其药用盐。该发明的化合物是sEH抑制剂，可用于治疗通过sEH酶介导的疾病，如高血压。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制sEH和治疗与之相关的疾病的方法。

  公开号：

  WO2009049165A1
• 作为产物：
  描述：

  2,4-二氯-6-苯基-1,3,5-三嗪 、 甲胺 在 sodium hydroxide 作用下， 以 水 、 乙腈 为溶剂， 反应 0.25h， 生成 (4-chloro-6-phenyl-[1,3,5]triazin-2-yl)-methyl-amine
  参考文献：
  名称：

  [EN] NOVEL SEH INHIBITORS AND THEIR USE
  [FR] INHIBITEURS INÉDITS DE LA SEH ET LEUR UTILISATION

  摘要：

  该发明涉及新颖的sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体而言，该发明涉及符合以下式I的化合物：(I) 其中R1、R2、R3、R5a、R6a、A、B、Y、x和m的定义如下，并且其药用盐。该发明的化合物是sEH抑制剂，可用于治疗通过sEH酶介导的疾病，如高血压。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制sEH和治疗与之相关的疾病的方法。

  公开号：

  WO2009049165A1

文献信息

• [EN] NOVEL SEH INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE SEH ET LEUR UTILISATION
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009049157A1

  公开（公告）日：2009-04-16

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及新型sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体来说，该发明涉及符合以下式I的化合物：其中R1、R2、R4、R5、R6、A、B、Y、Z、n和m如下所定义，并其药学上可接受的盐。该发明的化合物是sEH抑制剂，可用于通过sEH酶介导的疾病治疗，如高血压。因此，该发明进一步涉及包含该发明的化合物的药物组合物。该发明还进一步涉及使用该发明的化合物或包含该发明的药物组合物来抑制sEH并治疗与之相关的病症的方法。
• [EN] DIAMINOTRIAZINE COMPOUND<br/>[FR] COMPOSÉ DE DIAMINOTRIAZINE
  申请人：BASF SE

  公开号：WO2015155129A1

  公开（公告）日：2015-10-15

  The present invention relates to diaminotriazine compounds of the formula (I) and to their use as herbicides. The present invention also relates to agrochemical compositions for crop protection and to a method for controlling unwanted vegetation.

  本发明涉及公式（I）的二氨基三嗪化合物及其作为除草剂的用途。本发明还涉及用于作物保护的农业化学组合物以及一种控制不良植被的方法。
• NOVEL sEH INHIBITORS AND THEIR USE
  申请人：Ding Yun

  公开号：US20100210656A1

  公开（公告）日：2010-08-19

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，本发明涉及符合以下式I的化合物：其中R1、R2、R4、R5、R6、A、B、Y、Z、n和m的定义如下，并且其药学上可接受的盐。本发明的化合物是sEH抑制剂，可用于治疗由sEH酶介导的疾病，例如高血压。因此，本发明还涉及包括本发明化合物的制药组合物。本发明还进一步涉及使用本发明化合物或包括本发明化合物的制药组合物来抑制sEH和治疗与之相关的疾病的方法。
• sEH inhibitors and their use
  申请人：GlaxoSmithKline, LLC

  公开号：US08173805B2

  公开（公告）日：2012-05-08

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及一种新型的sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，本发明涉及公式I所示的化合物，其中R1，R2，R4，R5，R6，A，B，Y，Z，n和m的定义如下，并且其药学上可接受的盐。本发明的化合物是sEH抑制剂，可用于治疗由sEH酶介导的疾病，如高血压。因此，本发明还涉及包含本发明化合物的药物组合物。本发明还涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制sEH和治疗与之相关的疾病的方法。
• Novel sEH Inhibitors and Their Use
  申请人：DING Yun

  公开号：US20100249137A1

  公开（公告）日：2010-09-30

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof. The compounds of the invention can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension, asthma, and COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，本发明涉及(Cis)-N-[4-氰基-2-(三氟甲基)苯基]甲基}-3-[4-甲基-6-(甲基氨基)-1,3,5-三嗪-2-基]氨基}环己烷羧酰胺；或其药学上可接受的盐，以及N-[4-氰基-2-(三氟甲基)苯基]甲基}-3-[4-甲基-6-(甲基氨基)-1,3,5-三嗪-2-基]氨基}环己烷羧酰胺；或其药学上可接受的盐。本发明的化合物可用于治疗由sEH酶介导的疾病，如高血压、哮喘和COPD。因此，本发明进一步涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物抑制sEH和治疗与之相关的疾病的方法。